Stocksigma LogoStocksigma Logo

Brooks Laboratories Approves Demerger of Manufacturing Business into Abridge Speciality

Brooks Laboratories' board approved the demerger of its Manufacturing Business into wholly owned subsidiary Abridge Speciality Limited on a going-concern

Brooks Laboratories Approves Demerger of Manufacturing Business into Abridge Speciality

Brooks Laboratories Ltd · Others (Uncategorized) · 14 Oct 2026, 11:52 pm

Brooks Laboratories Approves Demerger of Manufacturing Business into Abridge Speciality Brooks Laboratories' board approved the demerger of its Manufacturing Business into wholly owned subsidiary Abridge Speciality Limited on a going-concern basis. The demerged unit generated ₹8,287.26 lakhs (96.66% of total turnover) in FY26. Shareholders will receive 1 fully paid equity share of Abridge Speciality for every 1 share held in Brooks Laboratories, maintaining proportional mirror shareholding (52.62% promoter, 47.38% public). Post-scheme, Abridge Speciality will list on BSE and NSE and be renamed Brooks Laboratories Limited, while the residual trading entity will be renamed Xuri Lifesciences Limited. Listing is expected ~16 months from filing.

Original exchange filing (PDF)

More announcements from Brooks Laboratories Ltd

All Brooks Laboratories Ltd announcements